Bicycle Therapeutics plc
(NASDAQ:BCYC)
$13.92
0.08 (0.58%)
At Close: 4:00 PM
BCYC Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
BCYC Stock Price Today
Bicycle Therapeutics plc (BCYC) stock rallied over 0.58% intraday to trade at $13.92 a share on NASDAQ. The stock opened with a gain of 10.33% at $15.27 and touched an intraday high of $15.40, rising 0.58% against the last close of $13.84. The Bicycle Therapeutics plc in stock market went to a low of $14.14 during the session.
BCYC Stock Snapshot
$13.84
Prev. Close
589.93 Million
Market Cap
$14.14
Day Low
$15.27
Open
N/A
Number of Shares
$15.40
Day High
N/A
P/E ratio
-5.00
EPS (TTM)
13.49
Cash Flow per Share
N/A
Free Float in %
9.81
Book Value
370525.00
Volume
BCYC Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Babraham Research CampusCambridge, CB22 3ATGB
Website:https://www.bicycletherapeutics.com
Contact #:44 1223 261 503
Company Information
EmployeesN/A
Beta0.74
Sales or Revenue$24.83 Million
5Y Sales Change69.50%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Peers
Frequently Asked Questions
What is the current Bicycle Therapeutics plc (BCYC) stock price?
Bicycle Therapeutics plc (NASDAQ: BCYC) stock price is $13.92 in the last trading session. During the trading session, BCYC stock reached the peak price of $15.40 while $14.14 was the lowest point it dropped to. The percentage change in BCYC stock occurred in the recent session was 0.58% while the dollar amount for the price change in BCYC stock was $0.08.
BCYC's industry and sector of operation?
The NASDAQ listed BCYC is part of Biotechnology industry that operates in the broader Healthcare sector. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Who are the executives of BCYC?
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE
Co-Founder, Non-Executive Director & Member of Scientific Advisory Board
Dr. Kevin Lee M.B.A., Ph.D.
Chief Executive Officer & Executive Director
Mr. Lee H. Kalowski M.B.A., MBA
Pres & Chief Financial Officer
Mr. David E. Borah CFA
Vice President of Capital Markets & Investor Relations
How BCYC did perform over past 52-week?
BCYC's closing price is 0.73% higher than its 52-week low of $14.14 where as its distance from 52-week high of $33.49 is -0.38%.
How many employees does BCYC have?
Number of BCYC employees currently stands at N/A. BCYC operates from Babraham Research Campus, Cambridge, CB22 3AT, GB.
Link for BCYC official website?
Official Website of BCYC is: https://www.bicycletherapeutics.com
How do I contact BCYC?
BCYC could be contacted at phone #44 1223 261 503 and can also be accessed through its website. BCYC operates from Babraham Research Campus, Cambridge, CB22 3AT, GB.
How many shares of BCYC are traded daily?
BCYC stock volume for the day was 370525.00 shares. The average number of BCYC shares traded daily for last 3 months was 435.31 Thousands.
What is the market cap of BCYC currently?
The market value of BCYC currently stands at $589.93 Million with its latest stock price at $13.92 and N/A of its shares outstanding.